A new clinical study today announced by Phoenix-based biomedical company Insys Therapeutics will explore the effectiveness of the company’s patented CBD oral solution on symptoms of early psychosis and the drive behind excessive eating behaviour that accompanies the use of antipsychotic medication.
The research will be included as part of the company’s collaboration with UC San Diego’s Center for Medicinal Cannabis Research (CMCR).
“As a result of this new study announced today, we expect to learn whether CBD reduces symptoms and improves cognition in early psychosis,” said Kristin Cadenhead, MD, professor of psychiatry at UC San Diego.
“In addition, we plan to explore the effect of CBD on the biological response to psychosocial stress, and the effect of CBD on the eating behavior induced by antipsychotic medication,” said Dr. Cadenhead.
CMCR Director Igor Grant, MD said: “Cannabinoids such as CBD deserve rigorous study into their possible value in the treatment of neuropsychiatric disorders.
“We are pleased that through our collaboration with INSYS we have an opportunity to advance the field,” said Dr. Grant.
In addition to the Clinical Study of Cannabidiol in Early Psychosis, INSYS and CMCR are continuing with a study of oral CBD in pediatric patients with autism, which is expected to start in 2019.
INSYS president and CEO said the research into psychosis and autism are among several other studies that its clinical research teams are considering.
“Our partnership with CMCR has the potential to significantly advance the clinical science of pharmaceutical cannabinoids across a range of indications,” said Saeed Motahari.